Hormonal development therapy (HDT) in hypogonadism in long-term view

Heinz, Marlene

doi:10.1016/j.bpobgyn.2009.11.013

Cited by 6 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…El uso de anticonceptivos orales para terminar el desarrollo puberal están desaconsejados ya que las dosis de estrógenos sintéticos y las progestinas de síntesis que contienen pueden interferir en el adecuado desarrollo de las mamas y el útero 6 . La sustitución hormonal con estrógenos y progestinas deberá prolongarse hasta por lo menos los 30 años, llegando idealmente hasta una edad normal de menopausia 31 .…”

Section: Cuanto Dura La Inducción Y Como Continuar La Sustituciónunclassified

Inducción de la pubertad en el síndrome de Turner

2011

Rev. chil. pediatr.

View full text Add to dashboard Cite

Section: Cuanto Dura La Inducción Y Como Continuar La Sustituciónunclassified

Inducción de la pubertad en el síndrome de Turner

2011

Rev. chil. pediatr.

View full text Add to dashboard Cite

“…A long-term substitution of sex hormones is essential for both male (1,2) and female (1,3) patients to prevent health problems associated with sex hormone deficiency. These include the reduction of bone mineral density (4,5) and the development of a metabolic syndrome in men (6) or some of its components, such as dyslipidemia or an increase in central fat in women (7).…”

Section: Introductionmentioning

confidence: 99%

Effects of adolescence-onset hypogonadism on metabolism, bone mineral density and quality of life in adulthood

Tam¹,

Huebner

Hofbauer

2015

Journal of Pediatric Endocrinology and Metabolism

View full text Add to dashboard Cite

In a cross-sectional study of 54 patients with adolescence-onset hypogonadism (33 females, 21 males; age range: 19-40 years), medical care, quality of life, and health status were assessed. Most patients had received adequate medical care with short cumulative periods of interruption of hormone replacement. The prevalence of the metabolic syndrome was 27% in females and 19% in males. In comparison to the general population, females had both a lower bone mineral density (dual-energy X-ray absorptiometry, Z-score=-0.8, p<0.001) and a higher prevalence of obesity (age 19-29 years: study population 35%, general population 4%). The body fat percentage (dual-energy X-ray absorptiometry) was significantly elevated (age 19-29 years: females Z-score=+1.8, p<0.001, males Z-score=+2.4, p=0.001). Quality of life (SF-36) was normal. Despite adequate treatment, patients with early-onset hypogonadism are prone to develop signs and symptoms consistent with inadequate hormone replacement. A successful transition from pediatric to adult medicine seems important to optimize treatment outcomes.

show abstract